Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scenario .... Now what are the chances that some groups spend a little capital to walk the share price down where it allows them to buy call options at a more profitable price
Hmmmm..... just think many more retail investors should be aware of the games and thats exactly what this walk down is .... a game.
Hold onto those shares.... don't fumble or let anyone strip those shares from you! Peregrine about to go in for the score and we will be at $7 soon enough!
over 2300 in april calls this morning...
1,300 $1's...
1,000 $3's...
Ummmm.... I do remember hearing that on here before : )
I just wanted to see if AF was listening... maybe I should have said we will never see $117 within 2 months : )
All is quiet out in Tustin... hopefully they are preparing a nice PR before the week is out
Could be that Trojan Horse though as well.... : )
Its amazing the manipulation that can .....I mean the managed markets that can exist on all facets of publicly traded companies.
I still am waiting patiently for Peregrine to deliver the knock out punch with incredible MOS data.
I think we will have news in the a.m.... more details for Cotara just to get them backed up in the corner before the big Bavi news sends longs on their feet and others in shock.
That he is that Garnick fellow:.."he sees promise in both bavituximab and Peregrine’s other drug candidate, Cotara for brain cancer. Cotara is being studied for the treatment of gliboblastoma multiforme, or GBM."
In my opinion.... there is no other man qualified to tell Peregrine that Bavi works better than Avastin than the man (Garnick) who walked Avastin in the doors of the FDA and out with its 1st approval.
IMHO....Peregrine has been pitted up against Avastin for months and Garnick is weeks away from entering the FDA again and exiting with Bavi's 1st approval.
Rob Garnick and Bavituximab... love at first sight.
Question: What is it going to take for another pharmcaceutical company to attract the wealth of knowledge and expertise of veteran Rob Garnick away from Genentech? ... All you need is a drug thats better than his first hand knowledge of Avastin
"Peregrine Pharmaceuticals (PPHM) is an early-stage company working toward approval of its first product, a cancer drug.
Navigating the regulatory waters alone can be daunting for a small company. But Peregrine has a seasoned skipper for the important job: Robert Garnick, a 24-year veteran of Genentech. In his two decades at the biotech company (now part of Roche), Garnick oversaw 17 product approvals, including for top-selling drugs Rituxan, Herceptin, Avastin, and Lucentis."
-------------------------------------
http://www.minyanville.com/businessmarkets/articles/peregrine-pharmaceuticals-bavituximab-robert-garnick-steven/6/29/2011/id/35458
------------------------------------
Mr. Garnick tested and developed Avastin and "it is" the sole reason why he is at Peregrine because once he seen the early trial indicators of Bavituximab .... you don't think he realized the data and moa would be a success? He knows the Avastin data... and knows the Bavi data! This is the reasoning behind lining up trial after trial... after trial with Bavi because he is this confident.
I think some investors don't realize that Garnick was the man behind Avastin and this is showtime for Bavi data over the next month or two with possibly the knockout punch for "MOS" data.
Volume ( Twitter Posts Volume ) precedes Price.... My guess is the know the announcement is coming soon and trying to walk this down a little further before we make our next climb up
Dew... Do you still believe that Avid is cash flow negative after listening to the last conference call? This is one of the many falsehoods that have been spread about Peregrine over the past year.
In My Opinion... and I'm basing this solely on all your posts over the past year and anyone can see this... that you are promoting many of the major BP's such as Pfizer. Peregrine Pharmaceuticals will directly affect many of these BP's you promote thru all your posts and I believe this is the reason you are simply targeting Peregrine.
Peregrine's Avid was said to be cash flow negative... that is false
Peregrine you said just didn't have any thing in Cotara and the program dropped ... that is false as its FDA approved ph III trial moving forward
Peregrine was a placebo ?? ... that was the biggest falsehood of them all
The facts are many BP's are threatened over the emergence of Peregrine into the oncology field with Bavituximab and that may just be an understatement as Bavi just may become the next generation lead drug to fight all cancers
Replace Avastin? IMHO Peregrine can replace Roche! : )
Bavi could be the cornerstone of any BP and just may open the doors to much more than just to fight cancer
Bank loan pay I feel is a non-issue at this point... imo its a fact that they said "it was paid back early"... its just the reasoning that differed on each side but Peregrine knows the end game and it was not the time to argue or have more news on the wire regarding Peregrine refusing to pay back the loan.
"This was also a very strong quarter for our manufacturing subsidiary, Avid Bioservices, as we are on track for another record year of manufacturing revenues. We are also making steady progress in advancing the bavituximab program on multiple clinical fronts with important clinical milestones anticipated to occur over the coming months. Upcoming clinical milestones for the program include key median overall survival endpoints in pancreatic and front-line non-small cell lung cancer and final results from our second-line non-small cell lung cancer study in which we discovered discrepancies and have subsequently been intensely reviewing. The goal of this review is to be able to generate a final data set that we believe could be used to support advancing the program into a pivotal trial."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82395522
Lets go Peregrine... give us a little "interim" update in the a.m.! : )
Job Posting Removed/Filled? : Exec Assistant ... now 3 left used to be 4 openings
http://www.peregrineinc.com/about-us/careers.html
Dr. Jack West has a video out: "Why Don’t We Routinely Use Two Drug Combinations for Previously Treated Advanced NSCLC?"
http://blog.lungevity.org/category/lung-cancer/
.... I expect Bavituximab to further prove him wrong... and hope to see him retract his previous article about Peregrine:
http://blog.lungevity.org/2012/10/05/bavituximab-a-great-story-that-turns-out-too-good-to-be-true/
I wouldn't even want to imagine the possibility of some form of governmental ownership of the Bavi pipeline ... much less profitable for the stockholders I would imagine.
There is one way that I'd be for it.... of course Bavi has to be proven to work with all cancers first!
Next.... IF the payout was somewhat comparable to what we would get for a private buyout and the money saved by the government as well as making a profit to all other countries would take our 17 Trillion national debt off the table and give us a surplus.
Do the large Middle Eastern oil producing countries have a national debt like most others? No way
I just hope we get some good news this week.
I had the same idea....its exactly the type of out of box thinking that you never know could happen. Even Peregrine partnering with them ... how much grant money does NIH send out for innovation ?? If they like what they have in Bavi and the one major reason I like the NIH idea is they will have no doubt in their mind about "holding" any technology back
Bottom line is if the so called... "coding" errors never happened... and we did come close to partnering back a couple months ago? Ironically.... Peregrine sits in a better situation for these reasons:
1) Other partnering BP's that didn't take things further may have thought about it more and realized that someone will be there to partner with them ... or teaming up with someone else to pool monies together
2) More data will be coming out.... much more data... and longer "MOS"
Things happen for a reason.... maybe Peregrine knew this all along ... hmmmm
GLTA!
I think they walked this down as far as they could yesterday and this morning.... turn around time
Good post! Undervaluation of Peregrine is the understatement of the year at this time in biotech stocks for sure. I know its difficult to bring up at times considering the price we sit at...and from the 9/24 fiasco but that will change. Analyst upgrades are coming ( I guess I should say IMHO ) and its only all a matter of time.
As for the theories on how we proceed... I like to hear all theories and conspiracies because you always have to be thinking out of the box... because I have a gut feeling that many medium sized BP's will be thinking out of the box to try and become the next biggest BP play.
If the BP has the cash... Peregrine will be listening. Lets just hope the analysts are listening because they will be part of driving this stock higher in the very short term before PR's continue to roll out of Peregrine.
... Peregrine mentioned as a competitor in a (CELG) Celgene article
just funny to see a drug company "Celgene" sitting at $79.84 and investors being told to watch out for "would be" competitor ... our little Peregrine.
"along with getting abraxane an expanded indication for pancreatic cancer ahead of would-be competitors like Threshold's (NASDAQ: THLD ) TH-302 and Peregrine's (NASDAQ: PPHM ) bavituximab."
http://www.fool.com/investing/general/2012/12/13/celgene-investors-what-to-watch.aspx
Now how often do you see that in an article? Our Peregrine got a 2nd look walking down "The Street".
I would like it done by this summer as well! : ) and ok... if its between 8B - 80B ( $61.50 - $ 615.00 )
If we never went from $5 to $1 but went from $5 to $50 ... we'd all want the $615
Since we went from $5 to 1 ..... and now to ?? I'd say the majority would be fine with $61.50 : )
I hope we do find out though this summer.... time to cash out
good point about the "Transcelerates Formation..." and although its at 10 members right now and they all have to put in funds for operation its basically just a merger it seems? to split profits from whats researched/developed among them? Wouldn't it be interesting if the buyout came exactly from that 10 member BP and they then have the wide reach to start running hundreds or thousands Bavi trials and research and they all share in the end profits.
Hostile takeover of DNA or Friendly Bid (from Roche)... what can Peregrine expect as Bavi is clearly beating out Avastin
Roche buys the remaining 44% of Genentech (DNA) that they don't already own.... bids started in the 80's ... Roche special committee wanted as high as $116 and settled priced was $95 pps for a total of 43.7 Billion... thats 43.7 Billion for 44% of the company.
some articles stated this buyout as high as 46B but lets just play it conservative and say 50% of the company for 40B so that gives us 100% valued at about 80B market cap
If Bavi will take the route of surpassing Avastin ( mainly in safety and "mos" ) the future is brighter than we may think.
For Peregrines case... 80 Billion / 130M OS = $615 pps
This is just an educated guess but with the BP's pipeline decreasing and as stated many drugs going off patent can and should Peregrine warrant the same value? I think so
http://247wallst.com/2009/03/12/roche-buyout-for-genentech-dna-a-game-well-played/
"The lawsuit contends Roche’s bid was timed to capitalize on general market turmoil and a decline in Genentech’s stock price."
http://dealbook.nytimes.com/2008/07/24/genentech-investor-sues-to-block-roche-bid/
... How many would sue over a buyout price of $615 ?
Sabotage? ... well I hope that is something we never have to worry about and if so....cant we enlist the help of the "Sons of Anarchy"? They in Cali...right? :) They can finally get out of the illegal drug business....and invest in a legit drug business lol : )
Ok....off topic but trying to get a smile out there on this down day....
GLTA tomorrow!
I want to believe the forces are greater to push Peregrine and its pipeline thru the political arena... than those on the opposite side. It will not go down without a fight since the company is already public and there the path has been set up already. If this was a private company ... and very limited scope of people that were aware of it then maybe 40 years from now you'd have a group of people talking of the automobiles that can run without gas but no proof ... and stories of a cancer drug once existed could battle cancer as simple as the common cold.
Its easy to buy out a few here and there.... but Peregrine has thousands of supporters behind it at this point but as we have all seen the power of the FDA trumps all and that is the value of Mr. Garnick at this stage of the game!
-back from June 29, 2011 but shows how we should value Steve King for making this move...of recruiting Garnick but then again... once he seen the potential of Bavi... Garnick couldn't give up the chance of a lifetime!
http://www.minyanville.com/businessmarkets/articles/peregrine-pharmaceuticals-bavituximab-robert-garnick-steven/6/29/2011/id/35458
-----------------------------
"Garnick has a deep understanding of the Food and Drug Administration process, particularly for approval of biotech treatments, King says. The CEO considers his company fortunate to have someone with Garnick’s long history with the agency.
“Rob is the ringmaster,” King says."
-----------------------------
GLTA!
I think that extra production facility may come in handy to max the production of Bavi if Avid is unable to meet the full demand .... once the following side effect risks are considered vs Bavi's
Side Effects of Avastin below from: http://www.avastin.com/patient/lung/side-effects/index.html
The most serious side effects (not common, but sometimes fatal): (from the use of Avastin)
• Gastrointestinal (GI) perforation. A hole that develops in your stomach or intestine. Symptoms include pain in the abdomen, nausea, vomiting, constipation, or fever
• Wounds that don’t heal. A cut made during surgery can be slow to heal or may not fully heal. Avastin should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed
• Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, do not take Avastin
Other possible serious side effects:
• Abnormal passage in the body. This forms from one part of the body to another and can sometimes be fatal
• Stroke or heart problems. These include blood clots, mini-stroke, heart attack, and chest pain. These can sometimes be fatal
• Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on Avastin and after stopping treatment
• Nervous system and vision problems. Symptoms include high blood pressure, headache, seizure, sluggishness, confusion, and blindness
• Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal
• Infusion reactions. These may include difficulty breathing, chest pain, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion reactions
• Fertility issues for women. Avastin could cause a woman’s ovaries to stop working and may impair her ability to have children
FTM... very much appreciated! and to all sorry about throwing that 3,000 # of trials out there... thought I heard that on here... maybe it was 3,000 patients in total?
Lets go Peregrine... lots of news to come!
Maybe we should keep an eye out for any of those 3,000 trials with Avastin being reduced, delayed, cutback...etc. The word will be out there soon enough and the more questions being asked and directed towards the doctors about Bavi.... the better.
I look forward to the second? Wall Street Journal article about Peregrine and Bavi
I believe many years ago... someone had posted that the WSJ wrote a piece about Peregrine ?
I can agree with you and lets assume that is the case where every cancer drug that is sold now works better, safer, points to a longer "mos" then I would see that as Peregrine being welcomed a little more with open arms since BP's can still use their current drugs along with Bavi.
but.... I could be wrong .... just that we didn't test Bavi with Avastin for instance ..right? We tested it with "generic" drugs not tied to or "owned" by any BP currently and lets assume Bavi goes to market for FDA approval for 2nd or 1st line NSCLC then no one else can use Bavi than those who purchase the pipeline.... right?
Maybe I am looking at this wrong... just feel that if option A) is Bavi and gives you 20 months "mos" with no side effects and option B) gives you another drug that gives you 10 months "mos" with side effects
I assume the choice is clearly A) Bavi
Its another story I think though... if the FDA approves this as a drug that can be mixed with any other drug which would appease the oncology drug industry but I don't think thats the case at this point?
Maybe its approved and later approved for more "general" use where Peregrine and Partner? have to sign deals with each BP that wants to use it?
Either way we look at it....the future is brighter with Bavituximab and lets hope the chart can hit north of $400.00 one day : )
Peregrine did remind us all that "reaching" MOS on their trials would be announced once its reached. So just like back in the pre-Sept 24 days ..... the euphoria begins again... and if we hit $5 on the stand alone doubling of "MOS", the chart will grow exponentially as we again will toss out TA analysis till we reach what $$$ ?
GLTA! : )
I did see that but didnt want to mention that hack job of a price increase....."Mr. Roth...it looks like we may have to increase our price target since its already doubled again and heading back up...should I target it properly at ..... (Mr. Roth jumps in as his coffee spills on his lap) "Its already moving back up?!! I think the Street really is underestimating those IHUB guys! @#$%! just inch it up the target a little to $1.35.... I havent heard back from the bosses yet to call it just yet. (Analyst thinking...Hmmmmmm... ) Ithought you were the boss?
You have been here for 6 months ....the boss is Mr. Agen
Agen??
Agenda for code you moron.....If you want to be working the boards responding to Posts...you best smartin up!
"Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer."
http://www.marketwatch.com/story/top-moving-nasdaq-stocks-in-the-market-nasdaq-swsh-nasdaq-pphm-2012-12-13?siteid=bigcharts&dist=bigcharts
New approach .... some don't like change as they can't seem to come to terms with allowing the oncology field of cancer treatments to be taken over by Peregrine and the millions and billions of dollars of research and marketing by some current drugs to be put on the back shelf and replaced by simply a superior alternative of treatment with less side effects and increased "MOS".
This is what the analysts should be discussing and where are our new price targets? Get into your bosses office and get the "ok" already to upset the competition! : )
GLTA!
New Job Posting: Sr. Research Associate / Analytical Biochemistry
Job Code: at time I viewed there was no job code...
Job Status: "Sourcing" ... as other jobs listed state: "interviewing"
http://www.peregrineinc.com/about-us/careers.html?task=view&id=38
"Within Process Science, the Analytical Biochemistry group performs routine analytical testing, supports protein characterization efforts, and develops assays to demonstrate purity, comparability, and functionality of Peregrine products. We seek an experienced analytical scientist to join the Analytical Biochemistry group. The candidate will collaborate with colleagues in Process Science, Quality Control and Manufacturing departments to provide assay methods to support both development and manufacturing. The candidate will design and execute well-controlled experiments, compiling, analyzing and reporting results to his/her supervisor in a clear and concise fashion. In addition, he/she will participate in weekly departmental meetings, providing updates to the group."
We can only...only hope that this is the case and we would be living thru historic times and trial data. I still think back on that conference call of mid summer 2012...June? I believe and from that moment you "clearly" notice the excitement in Kings voice as well as the others on that call. I had the gut feeling then that the Bavi years of research have paid off. I would advise anyone just jumping into this stock to listen to that conference call and with all the highly educated and well written posters that lay out the science ...history...and probabilities to come I think IMHO you will come to the same conclusion! Its a buy
GLTA!
So looks like S8 filed and future grant price locked in at $1.21? ...... This should bring Steve King from 1.3M+ shares .....to 1.8M+ shares as I assume he gets the max of 500k shares on the next go around.
Lets close the books on the options .....and hopefully they all are good and finally ready to officially let SS Peregrine off the docks and set sail to open seas. May the wind be always at our backs!
Thinking outside the box... interim may also allow the possibility that they announce "milestone" qualifiable data that allows options to be granted sooner..... than later.
Thanks CJ for the transcript once again.... ! sure does make it much easier to review all the little details and key phrases : )
" They will hit the ATM again prior to 2014.."
I am at peace of mind with my investment and we can all have opinions of exactly how Peregrine has moved up the ranks to this point and how they should navigate the rest of the way through but until they fail I can't argue much more on why,when,how they make certain moves at this critical... or as Garnick said.."pivotal" time. That said...you are right... they just may hit the ATM again prior to 2014 but if they do I will be fine with that because they will do so for one of three reasons:
1) They need the money ..... not likely
2) They need the money for leverage during partnering talks .... more likely
3) They may be helping out someone lock in on the bottom.... possibly
I would go with they need the money on the books.... more so for strategic presentation purposes for partnering...etc
Bottom line.... I'll give them "some" benefit of the doubt and call it necessary to reach our goals because at this point I think we should all be much more at ease with our investment.
We are literally invested in a groundbreaking stock within the medical field.
Since we have been talking about outstanding shares... this is just a little reminder of another stock that once was at our stage at this point right now.
http://www.foodprocessing.com/industrynews/2012/coca-cola-stock-split.html
Coca-Cola Approves Two-for-One Stock Split
07/11/2012
The shareowners of The Coca-Cola Co., Atlanta, on July 10 approved a two-for-one stock split and an increase from 5.6 billion to 11.2 billion in the number of authorized shares of the company's common stock.
The record date for the stock split is expected to be July 27, with new shares expected to be distributed on or about Aug. 10. Each shareowner of record on the close of business on the record date will receive one additional share of common stock for each share held.
The split is the 11th in the stock's 92-year history and the first in 16 years. With all dividends reinvested annually, one share of common stock purchased for $40 in 1919 would be worth approximately $10.3 million today, the company said."
----------------------------------------------
Here we sit at 130M outstanding shares and will we get our first stock split in the future? Absolutely if we were able to keep our own ticker... but the stock splits will be coming from the BP that eventually buys us out (regionally) .... and that will not come for 2-4 years from now...for now we will settle for one hefty down payment moving our stock much closer to that $117 as we will never see that $1.17 ever again. : )
All the dots are being connected.... and the less negative articles we see from The Street its only because they are finally sitting down with a magnifying glass ...for once looking at all the dots ready to be connected!
SEC option dates:
http://www.secform4.com/insider-trading/704562.htm
I just looked at Steven Kings since he has the most...and the past 2 years they have been granted in Feb and May so the options that were approved last ASM ... will they save some for the new BOD's.... affiliated with their future Partner? and at what price will they land them at this February...?
May 8, 2012 Granted:
Granted 500,000 .... total = 1,373,500
price of .46
Feb 21, 2012:
Granted 267,439 & 82,561 ... total = 873,500
price of .95
May 2, 2011:
Granted 142,500 ....... total = 553,500
price of 2.44
Feb 1, 2010:
Granted 221,000 ... total = 411,000
price 2.93
congrats on the soon to be receiving PHD! One last comment on the OS... Any biotech stock of course raises money in many ways and one obvious way is to give a portion of the company. For all of us.... thankfully Peregrine has not done that.
Next... we relied upon the ATM mostly ( Avid helped big as well ) and here we sit at 130M.
The only reason I say 100/130/150/250M OS doesn't matter is because whatever the amount it takes (hopefully honestly needed) to complete the mission .... well I accept it takes that amount of money to complete the mission and the Bavi platform/pipeline is IMHO... I expect to bring in a much larger (historic) share of revenue that offsets this ATM spending that was needed to build out the Bavi pipleline.
Overall.... most biotech stocks do overspend to try and get an FDA approval or partner or buyout and don't ever get the return back... thus the reason the ratio of 1:5 bio stock makes it. This 1:5 may make it .... but how many can make like Bavi? as we see the Bavi Pipeline readies itself for the national scene and thats where I believe its headed as it will be written up big time in the NY Times and many more cancer research magazines.
I guess the bottom line is we could have 1 of the top drugs in history that is going to open the gate to allow our immune system do its job against many cancers and when I see that type of future market cap we can reach.... yes, as someone mentioned The Microsoft of the Biotechs.... and I do hope we can exit this race for Bavi and limit it to our current OS mark of about 130M.
I expect many positive outlooks and yes... new analysts to not as for their bosses ok to initiate coverage on a stock we all know is heading to much higher places.
I understand.... but just feel that we are soo close to data...details...and a deal and do believe that we are that Microsoft biotech company. I would have loved to have made it with $80M shares OS but I can surely be at peace knowing we own the entire pipeline.....absolutely everything.....wrapped beautifully with IP global rights and many other biotechs are making partnering deals with the same OS ....plus not owning 100% of the pipeline.....plus giving away the BP share on their partbering deals. It does take money to build up a pipeline....and I know of no other that exists with a Bavi pipeline potential....and their own manufacturing that makes a profit....and Imaging that could be another standalone entity in the future.....and Cotara.
Where the heck are the new analysts that can analyze and predict what we have all seen for months....? Oh.... I forgot ....if they cover any other oncology drug makers they may hurt yheir feelings. Start leading and stop following and asking your boss if its ok to initiate coverageon Peregrine. This stock at this time should have a $10 target for Cotara...imaging... and Avid!
Once we get more positive MOS data...we then climb by dollars...not 4 friggin decimal places.
Its possible that they could have appealed / argued the "default" that required them to pay back the loan but they would be going against their current view of "major discrepancies" so on one hand they are major for many still ongoing theories.....and the same time its not major so they can argue against loan default?
I think they could have surely argued the side to keep the money but imho....this type of crisis 101 management calls them to pay it back....as the sooner its out of the news the quicker the recovery.
They already had their plate full for what we know now as "internal review".
Still many theories can be examined.... and I dont think it matters much as everyone from shorts to longs to bankers to internal reviews....are all trying to maximize what they can before the fat lady sings.
Bankers made some monet on the default...shorts money days are numbered and that leaves us longs and internal reviewers to finally be looking at what could be a FDA PR "breakthru" once we start seeing MOS trends.
There are soo many small biotechs that make it.....that make our OS look good! We are not going to just make it......we are going to "revolutionize" the oncology field with MOS #'s that are historic so as I said before....100M or 130M or 150M or 250M OS simply does not matter with our pipeline.